For instance, it is shown that FCGBP is significantly associated with a better overall prognosis and disease-specific survivals in head and neck cancer, colon cancer, and osteosarcoma patients [25,26,27], while in ovarian and prostate cancers, the high expression of FCGBP was associated with poorer overall survival [28]. This evidence concerns the gene FCGBP and prostate carcinoma.